Table 2.
Association between baseline patient characteristics and risk of olaparib toxicity.
| Categories | SAE within 6 Months * Odds Ratio † [95% CI] |
p-Value † |
|---|---|---|
| Age at olaparib initiation (years), (27 ‡), for each additional year | 1.01 [0.99; 1.03] | 0.13 |
| ECOG-PS > 1, (27 ‡) | 2.66 [0.42; 22.5] | 0.31 |
| Body mass index (kg/m2), (25 ‡), for each additional unit | 1.03 [0.99; 1.07] | 0.10 |
| Serum albumin (g/L), (20 ‡), for each additional unit | 0.95 [0.91; 1.00] | 0.10 |
| Renal insufficiency, (27 ‡), Cockcroft–Gault estimated clearance < 60 mL/min | 0.77 [0.15; 3.85] | 0.75 |
| Hemoglobin (g/dL), (26 ‡), for each additional unit | 0.93 [0.72; 1.18] | 0.57 |
| Olaparib formulation (27 ‡), capsule (reference) vs. tablet | 2.14 [0.44; 11.3] | 0.34 |
| Olaparib introduction setting (27 ‡), maintenance (reference) vs. first relapse and beyond | 0.26 [0.03; 1.57] | 0.16 |
* SAE: significant olaparib-related adverse event defined by (i) grade III–IV adverse events, or (ii) adverse events resulting in dose reduction or treatment discontinuation. † p-value and odds-ratio computed using univariable logistic regression analysis. ‡ Number of patients with available data included in the logistic regression analysis. ECOG-PS: Eastern Cooperative oncology Group Performance status.